vs

Side-by-side financial comparison of Ellington Financial Inc. (EFC) and MEDIFAST INC (MED). Click either name above to swap in a different company.

Ellington Financial Inc. is the larger business by last-quarter revenue ($78.2M vs $75.1M, roughly 1.0× MEDIFAST INC). On growth, Ellington Financial Inc. posted the faster year-over-year revenue change (8.7% vs -36.9%). Over the past eight quarters, Ellington Financial Inc.'s revenue compounded faster (1.8% CAGR vs -34.4%).

Ellington Management Group is an American hedge fund firm. As of June 2019, the firm was reportedly managing $8.5 billion in structured products and other credit instruments.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

EFC vs MED — Head-to-Head

Bigger by revenue
EFC
EFC
1.0× larger
EFC
$78.2M
$75.1M
MED
Growing faster (revenue YoY)
EFC
EFC
+45.6% gap
EFC
8.7%
-36.9%
MED
Faster 2-yr revenue CAGR
EFC
EFC
Annualised
EFC
1.8%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EFC
EFC
MED
MED
Revenue
$78.2M
$75.1M
Net Profit
$22.6M
Gross Margin
69.4%
Operating Margin
7.4%
-10.4%
Net Margin
28.9%
Revenue YoY
8.7%
-36.9%
Net Profit YoY
-26.2%
EPS (diluted)
$0.10
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EFC
EFC
MED
MED
Q4 25
$78.2M
$75.1M
Q3 25
$82.8M
$89.4M
Q2 25
$92.5M
$105.6M
Q1 25
$82.9M
$115.7M
Q4 24
$72.0M
$119.0M
Q3 24
$67.0M
$140.2M
Q2 24
$91.2M
$168.6M
Q1 24
$75.5M
$174.7M
Net Profit
EFC
EFC
MED
MED
Q4 25
$22.6M
Q3 25
$29.5M
$-2.3M
Q2 25
$42.9M
$2.5M
Q1 25
$31.6M
$-772.0K
Q4 24
$30.7M
Q3 24
$16.2M
$1.1M
Q2 24
$52.3M
$-8.2M
Q1 24
$26.9M
$8.3M
Gross Margin
EFC
EFC
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
EFC
EFC
MED
MED
Q4 25
7.4%
-10.4%
Q3 25
31.1%
-4.6%
Q2 25
38.3%
-1.0%
Q1 25
37.3%
-1.1%
Q4 24
28.0%
0.6%
Q3 24
24.0%
1.5%
Q2 24
52.8%
-4.7%
Q1 24
42.2%
4.5%
Net Margin
EFC
EFC
MED
MED
Q4 25
28.9%
Q3 25
35.7%
-2.5%
Q2 25
46.4%
2.3%
Q1 25
38.2%
-0.7%
Q4 24
42.6%
Q3 24
24.1%
0.8%
Q2 24
57.4%
-4.8%
Q1 24
35.6%
4.8%
EPS (diluted)
EFC
EFC
MED
MED
Q4 25
$0.10
$-1.64
Q3 25
$0.29
$-0.21
Q2 25
$0.45
$0.22
Q1 25
$0.35
$-0.07
Q4 24
$0.23
$0.08
Q3 24
$0.19
$0.10
Q2 24
$0.62
$-0.75
Q1 24
$0.32
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EFC
EFC
MED
MED
Cash + ST InvestmentsLiquidity on hand
$201.9M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.8B
$198.9M
Total Assets
$19.4B
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EFC
EFC
MED
MED
Q4 25
$201.9M
$167.3M
Q3 25
$184.8M
$173.5M
Q2 25
$211.0M
$162.7M
Q1 25
$203.3M
$164.6M
Q4 24
$192.4M
$162.3M
Q3 24
$217.7M
$170.0M
Q2 24
$198.5M
$163.5M
Q1 24
$187.5M
$156.4M
Stockholders' Equity
EFC
EFC
MED
MED
Q4 25
$1.8B
$198.9M
Q3 25
$1.8B
$214.7M
Q2 25
$1.7B
$216.0M
Q1 25
$1.6B
$211.0M
Q4 24
$1.6B
$210.1M
Q3 24
$1.6B
$207.3M
Q2 24
$1.6B
$205.3M
Q1 24
$1.5B
$211.0M
Total Assets
EFC
EFC
MED
MED
Q4 25
$19.4B
$248.0M
Q3 25
$17.8B
$268.2M
Q2 25
$17.1B
$269.3M
Q1 25
$16.6B
$280.0M
Q4 24
$16.3B
$284.2M
Q3 24
$16.0B
$291.2M
Q2 24
$15.1B
$293.5M
Q1 24
$15.1B
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EFC
EFC
MED
MED
Operating Cash FlowLast quarter
$-925.5M
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
0.0%
1.8%
Cash ConversionOCF / Net Profit
-40.92×
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EFC
EFC
MED
MED
Q4 25
$-925.5M
$-5.3M
Q3 25
$-290.4M
$12.1M
Q2 25
$-210.5M
$-3.4M
Q1 25
$-126.4M
$3.4M
Q4 24
$-430.5M
$-4.9M
Q3 24
$-141.7M
$9.1M
Q2 24
$-88.6M
$13.1M
Q1 24
$-59.5M
$7.3M
Free Cash Flow
EFC
EFC
MED
MED
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
EFC
EFC
MED
MED
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
EFC
EFC
MED
MED
Q4 25
0.0%
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
0.0%
1.9%
Q3 24
0.0%
1.0%
Q2 24
0.0%
1.1%
Q1 24
0.0%
1.1%
Cash Conversion
EFC
EFC
MED
MED
Q4 25
-40.92×
Q3 25
-9.84×
Q2 25
-4.90×
-1.36×
Q1 25
-3.99×
Q4 24
-14.04×
Q3 24
-8.76×
8.04×
Q2 24
-1.69×
Q1 24
-2.21×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons